P-763. Assessment of the in vitro potency of anti-mycobacterial agents against clinical Mycobacterium avium complex (MAC) pulmonary isolates: implications of intravenous and inhaled amikacin breakpoint reporting
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.958
Abstract: Abstract Background MAC pulmonary disease is associated with significant morbidity and requires multi-drug treatment for extended periods. The novel dosage form amikacin liposome inhalation suspension (ALIS) represents a much-needed treatment option and is noted to… read more here.
Keywords: mac pulmonary; vitro potency; mac; treatment ... See more keywords
Translatability of in vitro potency to clinical efficacious exposure: A retrospective analysis of FDA-approved targeted small molecule oncology drugs.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and translational science"
DOI: 10.1111/cts.13532
Abstract: In vitro potency is one of the important parameters representing efficacy potential of drugs and commonly used as benchmark of efficacious exposure at early clinical development. There are limited numbers of studies which systematically investigate… read more here.
Keywords: oncology; efficacious exposure; vitro potency; small molecule ... See more keywords
In Vitro Potency and Spectrum of the Novel Polymyxin MRX-8 Tested against Clinical Isolates of Gram-Negative Bacteria
Sign Up to like & getrecommendations! Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00139-22
Abstract: The polymyxins display excellent in vitro antimicrobial activity against most Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii isolates, but their clinical utility has been limited because of class-specific toxicity problems. Therefore, new polymyxin analogs with improved… read more here.
Keywords: mrx; novel polymyxin; potency spectrum; polymyxin ... See more keywords
In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer’s Disease
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Alzheimer's Disease"
DOI: 10.3233/jad-180165
Abstract: Diffusible amyloid-β (Aβ) oligomers are currently presumed to be the most cytotoxic Aβ assembly and held responsible to trigger the pathogenesis of Alzheimer’s disease (AD). Thus, Aβ oligomers are a prominent target in AD drug… read more here.
Keywords: disease vitro; preclinical pharmacokinetic; alzheimer disease; disease ... See more keywords